94 Comparative benefit of olaparib in recurrent BRCAm ovarian, breast, pancreatic and prostate cancer | International Journal of Gynecologic Cancer

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Poster

IGCS20_1061

94 Comparative benefit of olaparib in recurrent BRCAm ovarian, breast, pancreatic and prostate cancer

Free

Online download statistics by month:

Online download statistics by month: November 2020 to April 2024

	Abstract	Full	Pdf
Nov 2020	47	0	17
Dec 2020	17	0	5
Jan 2021	15	0	3
Feb 2021	8	0	4
Mar 2021	11	0	4
Apr 2021	18	0	4
May 2021	2	0	3
Jun 2021	0	0	3
Jul 2021	1	0	6
Aug 2021	0	0	3
Sep 2021	0	0	3
Oct 2021	11	0	17
Nov 2021	13	0	15
Dec 2021	4	0	4
Jan 2022	6	0	0
Feb 2022	8	0	0
Mar 2022	6	0	1
Apr 2022	10	0	1
May 2022	14	0	10
Jun 2022	8	0	4
Jul 2022	20	0	1
Aug 2022	10	0	2
Sep 2022	18	0	7
Oct 2022	4	0	4
Nov 2022	10	0	1
Dec 2022	10	0	2
Jan 2023	13	0	2
Feb 2023	16	0	0
Mar 2023	11	0	2
Apr 2023	6	0	2
May 2023	4	0	0
Jun 2023	4	0	0
Jul 2023	4	0	4
Aug 2023	4	0	3
Sep 2023	4	0	1
Oct 2023	0	0	1
Nov 2023	10	0	2
Dec 2023	17	0	0
Jan 2024	8	0	2
Feb 2024	14	0	1
Mar 2024	13	0	1
Apr 2024	6	0	2
Total	405	0	147